KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Sep 2025 value amounting to $73.9 million.

  • Acadia Pharmaceuticals' Free Cash Flow rose 16.97% to $73.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.1 million, marking a year-over-year decrease of 2.25%. This contributed to the annual value of $157.2 million for FY2024, which is 844.01% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Free Cash Flow of $73.9 million as of Q3 2025, which was up 15.55% from $64.0 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Free Cash Flow high stood at $85.4 million for Q4 2023, and its period low was -$76.3 million during Q1 2022.
  • Its 3-year average for Free Cash Flow is $30.2 million, with a median of $29.1 million in 2024.
  • Examining YoY changes over the last 5 years, Acadia Pharmaceuticals' Free Cash Flow showed a top increase of 457.97% in 2023 and a maximum decrease of 8,009.35% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$23.1 million in 2021, then decreased by 3.17% to -$23.9 million in 2022, then soared by 457.97% to $85.4 million in 2023, then slumped by 53.24% to $39.9 million in 2024, then rose by 16.97% to $73.9 million in 2025.
  • Its Free Cash Flow was $73.9 million in Q3 2025, compared to $64.0 million in Q2 2025 and $20.3 million in Q1 2025.